Acquired assets deliver positive clinical data for Astrazeneca, Genmab: Clinical Report
Plus: A look at recent stock moves on clinical developments
Two products obtained by pharmas via acquisitions had clinical readouts this week, though neither was enough to drive big stock moves. Eneboparatide, a peptide PTH1R antagonist and the centerpiece of a 2024 deal by Astrazeneca plc (LSE:AZN; NASDAQ:AZN) to acquire Amolyt Pharma S.A.S., met the primary endpoint in the Phase III CALYPSO trial to treat hypoparathyroidism. The composite endpoint measured normalization of albumin-adjusted serum calcium levels and independence from active vitamin D and oral calcium therapy, both at 24 weeks.
At the J.P. Morgan Healthcare Conference in January, Astrazeneca CFO Aradhana Sarin said eneboparatide represents a “blockbuster opportunity” to treat a disease with more than 200,000 patients in the U.S., Europe and Japan. CALYPSO will proceed to its final 52-week endpoint. Astrazeneca said its Alexion unit will share the data with global health authorities, but did not give a submission timeline...